Docstoc

Prospectus ANTIGENICS INC - 8-25-2010

Document Sample
Prospectus ANTIGENICS INC  - 8-25-2010 Powered By Docstoc
					                                                                                              Filed Pursuant to Rule 424(b)(3) and Rule 424(c)
                                                                                                                  Registration No. 333-149116

                                                                                                                                   August 25, 2010


                                                PROSPECTUS SUPPLEMENT NO. 29
                                            17,417,434 SHARES OF COMMON STOCK
                                                            ANTIGENICS INC.
      This prospectus supplement amends the prospectus dated March 16, 2009 (as supplemented on April 15, 2009, April 17, 2009, April 22,
2009, April 27, 2009, May 4, 2009, May 11, 2009, May 27, 2009, June 4, 2009, June 8, 2009, June 9, 2009, June 11, 2009, June 15, 2009,
July 7, 2009, July 15, 2009, August 3, 2009, August 5, 2009, September 11, 2009, September 18, 2009, November 12, 2009, January 5, 2010,
March 1, 2010, March 25, 2010, April 26, 2010, May 11, 2010, May 18, 2010, July 23, 2010, and August 9, 2010) to allow certain
stockholders or their pledgees, donees, transferees, or other successors in interest (the “Selling Stockholders”), to sell, from time to time, up to
8,708,717 shares of our common stock, which they have acquired in a private placement in the United States, and up to 8,708,717 shares of our
common stock issuable upon the exercise of warrants which are held by the Selling Stockholders named in the prospectus. On January 9, 2010,
these warrants expired unexercised.

     We would not receive any proceeds from any such sale of these shares. To the extent any of the warrants are exercised for cash, if at all,
we will receive the exercise price for those warrants.

      This prospectus supplement is being filed to include the information set forth in the Current Report on Form 8-K filed on August 25,
2010, which is set forth below. This prospectus supplement should be read in conjunction with the prospectus dated March 16, 2009,
Prospectus Supplement No. 1 dated April 15, 2009, Prospectus Supplement No. 2 dated April 17, 2009, Prospectus Supplement No. 3 dated
April 22, 2009, Prospectus Supplement No. 4 dated April 27, 2009, Prospectus Supplement No. 5 dated May 4, 2009, Prospectus Supplement
No. 6 dated May 11, 2009, Prospectus Supplement No. 7 dated May 27, 2009, Prospectus Supplement No. 8 dated June 4, 2009, Prospectus
Supplement No. 9 dated June 8, 2009, Prospectus Supplement No. 10 dated June 9, 2009, Prospectus Supplement No. 11 dated June 11, 2009,
Prospectus No. 12 dated June 15, 2009, Prospectus Supplement No. 13 dated July 7, 2009, Prospectus Supplement No. 14 dated July 15, 2009,
Prospectus Supplement No. 15 dated August 3, 2009, Prospectus Supplement No. 16 dated August 5, 2009, Prospectus Supplement No. 17
dated September 11, 2009, Prospectus Supplement No. 18 dated September 18, 2009, Prospectus Supplement No. 19 dated November 12,
2009, Prospectus Supplement No. 20 dated January 5, 2010, Prospectus Supplement No. 21 dated March 1, 2010, Prospectus Supplement
No. 23 dated March 25, 2010, Prospectus Supplement No. 24 dated April 26, 2010, Prospectus Supplement No. 25 dated May 11, 2010,
Prospectus Supplement No. 26 dated May 18, 2010, Prospectus Supplement No. 27 dated July 23, 2010, and Prospectus Supplement No. 28
dated August 9, 2010 which are to be delivered with this prospectus supplement.

       Our common stock is quoted on The NASDAQ Capital Market (“NASDAQ”) under the ticker symbol “AGEN.” On August 24, 2010, the
last reported closing price per share of our common stock was $0.78 per share.

Investing in our securities involves a high degree of risk. Before investing in any of our securities, you should read the discussion of
material risks in investing in our common stock. See “Risk Factors” on page 1 of the prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities
or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

                  THE DATE OF THIS PROSPECTUS SUPPLEMENT NO. 29 IS AUGUST 25, 2010
                                      UNITED STATES
                          SECURITIES AND EXCHANGE COMMISSION
                                                                    Washington, D.C. 20549



                                                                         FORM 8-K

                                                                   CURRENT REPORT
                                                         Pursuant to Section 13 or 15(d) of the
                                                           Securities Exchange Act of 1934
                                                                August 25, 2010
                                                 Date of Report (Date of earliest event reported)



                                                      ANTIGENICS INC.
                                                    (Exact name of registrant as specified in its charter)



                 DELAWARE                                                         000-29089                         06-1562417
             (State or other jurisdiction                                         (Commission                       (IRS Employer
                  of incorporation)                                               File Number)                     Identification No.)


                                              3 Forbes Road
                                              Lexington, MA                                                             02421
                                     (Address of principal executive offices)                                         (Zip Code)

                                                                                781-674-4400
                                                            (Registrant’s telephone number, including area code)




     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01    Regulation FD Disclosure
      On August 25, 2010, Antigenics Inc. announced that GlaxoSmithKline’s (GSK) herpes zoster vaccine candidate, which contains
Antigenics’ QS-21 Stimulon® adjuvant as a key component, has commenced Phase 3 clinical trials for the prevention of shingles. GSK plans
to study more than 30,000 patients globally for the debilitating condition which currently has limited treatment and prevention options
available.

     The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this current report on
Form 8-K.

Item 9.01    Financial Statements and Exhibits
     (d) Exhibits

     The following exhibit is furnished herewith:

             99.1     Press Release dated August 25, 2010
                                                                SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.

Date: August 25, 2010                                                 ANTIGENICS INC.

                                                                      By:                        /S/    G ARO A RMEN
                                                                                                          Garo Armen
                                                                                                     Chief Executive Officer
                                                EXHIBIT INDEX

Exhibit
 No.      Description of Exhibit

99.1      Press Release dated August 25, 2010
                                                                                                                                     Exhibit 99.1

                            THE FOURTH PRODUCT CANDIDATE CONTAINING ANTIGENICS’ QS-21
                                         IN PHASE 3 CLINICAL DEVELOPMENT

                              GSK Commences Phase 3 Clinical Trial with Shingles Vaccine Containing QS-21

LEXINGTON, MA – AUGUST 25, 2010 – Antigenics, Inc. (NASDAQ : AGEN) today announced that GlaxoSmithKline’s (GSK) herpes
zoster vaccine candidate, which contains Antigenics’ QS-21 Stimulon® adjuvant as a key component, has commenced Phase 3 clinical trials
for the prevention of shingles. GSK plans to study more than 30,000 patients globally for the debilitating condition which currently has limited
treatment and prevention options available.

QS-21 has demonstrated significant promise as a critical element in a number of investigational vaccine formulations addressing a wide variety
of indications, including infectious diseases, cancers, and Alzheimer’s disease. Antigenics is entitled to receive significant milestone payments,
in addition to royalties based upon sales of any vaccine containing QS-21 that is approved and marketed by its QS-21 licensees or their
partners.

“A significant number of products containing QS-21 continue to advance in the clinic,” said Garo H. Armen, PhD, chairman and CEO of
Antigenics. “This adjuvant has substantial revenue potential for Antigenics with no associated developments costs to the company.”

About QS-21 Stimulon Adjuvant
Antigenics’ QS-21 Stimulon adjuvant is one of the most widely tested vaccine adjuvants under development. QS-21 has not only become a
critical component in the development of preventative vaccine formulations across a wide variety of infectious diseases, but may also be
essential in enabling a new generation of therapeutic vaccines to treat cancer, infectious diseases and degenerative disorders. QS-21 is currently
being evaluated in approximately 20 vaccine indications, of which several are in late-stage clinical trials by Antigenics’ licensees, including
GlaxoSmithKline and JANSSEN Alzheimer Immunotherapy.

About Antigenics
Antigenics (NASDAQ: AGEN) is a biotechnology company working to develop treatments for cancers and infectious diseases. For more
information, please visit www.antigenics.com.

This press release contains forward-looking statements, including statements about clinical development programs for QS-21, potential future
milestone and royalty payments to Antigenics in connection with the development and commercialization of QS-21, and the significance of
QS-21 as a component in products under development. These forward-looking statements are subject to risks and uncertainties that could
cause actual results to differ materially. These risks and uncertainties include, among others,
Antigenics’ dependence on its collaborative partners such as GSK to successfully develop and commercialize products containing QS-21, the
scientific risk associated with the development of vaccines, the competitive risk that other sources of competitive adjuvants could become
available, difficulties or delays in manufacturing QS-21, and the risk factors described in the Risk Factors Section of our Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission for the period ended June 30, 2010. Antigenics cautions investors not to place
considerable reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this
document, and Antigenics undertakes no obligation to update or revise the statements. All forward-looking statements are expressly qualified
in their entirety by this cautionary statement. Antigenics’ business is subject to substantial risks and uncertainties, including those identified
above. When evaluating Antigenics’ business and securities, investors should give careful consideration to these risks and uncertainties.

Contacts:
Media: Brad Miles, (212) 477-9007 x17
Investors: Shalini Sharp, 800.962.2436